Literature DB >> 26856346

The Ontogeny and Population Variability of Human Hepatic NADPH Dehydrogenase Quinone Oxido-Reductase 1 (NQO1).

Luc R A Rougée1, Zoe Riches1, Jacob M Berman1, Abby C Collier2.   

Abstract

The NADPH dehydrogenase quinone oxido-reductase 1 (NQO1) enzyme is an antioxidant and metabolic enzyme that performs two electron reduction of quinones and other chemicals. Based on the physiologic role(s) of NQO1, we hypothesized that expression and activity of this enzyme would vary with age and other demographic variables. Cytosols from 117 archived human livers were investigated for changes in NQO1 with age, sex, obesity, and ethnicity. Protein expression but not activity of NQO1 was weakly negatively correlated with age (Spearman r = -0.2, P = 0.03). No sex differences were observed for either protein expression or activity and for ethnicity; Caucasians had greater NQO1 activity than Asians (P < 0.05). Overweight children had statistically significantly higher NQO1 activity as compared with ideal weight children (P < 0.05) although this difference was not observed in adults. These findings establish that NQO1 is approximately as active in children as adults. However, modeled NQO1 clearance (both allometric and physiologically based pharmacokinetics) predicted maturation at 23 to 26 years. This is almost certainly an overestimate, with error in the model resulting from a small sample size and inability to scale for age-related changes in hepatic cellularity and/or cytosolic protein content, and indicates a delay in reaching maximum clearance through the NQO1 pathway that is affected by physiologic development as much, or more than, biochemical development. Obesity may increase hepatic NQO1 activity in children, which is likely a protective mechanism in oxidative stress, but may also have significant implications for drug and chemical disposition in obese children.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26856346      PMCID: PMC4931887          DOI: 10.1124/dmd.115.068650

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  48 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

2.  Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.

Authors:  E M Howgate; K Rowland Yeo; N J Proctor; G T Tucker; A Rostami-Hodjegan
Journal:  Xenobiotica       Date:  2006-06       Impact factor: 1.908

Review 3.  Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation.

Authors:  F J Gonzalez; D W Nebert
Journal:  Trends Genet       Date:  1990-06       Impact factor: 11.639

4.  Enzymic differentiation of human liver: comparison with the rat model.

Authors:  O Greengard
Journal:  Pediatr Res       Date:  1977-05       Impact factor: 3.756

5.  NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations.

Authors:  A Gaedigk; R F Tyndale; M Jurima-Romet; E M Sellers; D M Grant; J S Leeder
Journal:  Pharmacogenetics       Date:  1998-08

6.  The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.

Authors:  Jill M Kolesar; Suzanne E Dahlberg; Sharon Marsh; Howard L McLeod; David H Johnson; Steven M Keller; Joan H Schiller
Journal:  Oncol Rep       Date:  2011-04-06       Impact factor: 3.906

7.  Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1.

Authors:  Christopher M Cabello; Warner B Bair; Alexandra S Bause; Georg T Wondrak
Journal:  Biochem Pharmacol       Date:  2009-04-24       Impact factor: 5.858

Review 8.  The ontogeny of drug metabolism enzymes and implications for adverse drug events.

Authors:  Ronald N Hines
Journal:  Pharmacol Ther       Date:  2008-03-05       Impact factor: 12.310

Review 9.  Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family.

Authors:  Vasilis Vasiliou; David Ross; Daniel W Nebert
Journal:  Hum Genomics       Date:  2006-03       Impact factor: 4.639

10.  Hepatic gene expression profiling in Nrf2 knockout mice after long-term high-fat diet-induced obesity.

Authors:  Dionysios V Chartoumpekis; Panos G Ziros; Apostolos Zaravinos; Ralitsa P Iskrenova; Agathoklis I Psyrogiannis; Venetsana E Kyriazopoulou; Gerasimos P Sykiotis; Ioannis G Habeos
Journal:  Oxid Med Cell Longev       Date:  2013-04-18       Impact factor: 6.543

View more
  3 in total

1.  Sex-, Age-, and Race/Ethnicity-Dependent Variations in Drug-Processing and NRF2-Regulated Genes in Human Livers.

Authors:  Jie Liu; Julia Yue Cui; Yuan-Fu Lu; J Christopher Corton; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2020-11-08       Impact factor: 3.922

Review 2.  Berry-Derived Polyphenols in Cardiovascular Pathologies: Mechanisms of Disease and the Role of Diet and Sex.

Authors:  Rami S Najjar; Casey G Turner; Brett J Wong; Rafaela G Feresin
Journal:  Nutrients       Date:  2021-01-27       Impact factor: 5.717

3.  Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.

Authors:  Shalenie P den Braver-Sewradj; Michiel W den Braver; Robin M Toorneman; Stephanie van Leeuwen; Yongjie Zhang; Stefan J Dekker; Nico P E Vermeulen; Jan N M Commandeur; J Chris Vos
Journal:  Chem Res Toxicol       Date:  2018-01-11       Impact factor: 3.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.